An investigator-initiated, open-label study evaluating the efficacy and safety of ustekinumab in patients with moderate to severe palmar plantar psoriasis

(Poster reference number 4733)
Shimrat Yaniv, Albert Einstein College of Medicine, Bronx, NY, United States; Alice Gottlieb, MD, PhD, Tufts Medical Center, Boston, MA, United States; Andrew Wang, MD, Tufts Medical Center, Boston, MA, United States; Melissa Michelon, Tufts Medical Center, Boston, MA, United States; Nicole Dumont, Tufts Medical Center, Boston, MA, United States; Shin-chung Au, MD, Tufts Medical Center, Boston, MA, United States; Todd Kerensky, MD, Tufts Medical Center, Boston, MA, United States.

Palmar plantar psoriasis (PPP) is a disabling and disfiguring form of psoriasis that is typically chronic and very difficult to treat. It is characterized by the presence of plaques and/or sterile pustules and fissures on the palms and soles, in addition to typical psoriatic plaques. We designed a small, open label: 24 week study to evaluate the safety and efficacy of ustekinumab, a fully human IL-12/23 monoclonal antibody, in patients with moderate to severe palmar plantar psoriasis. Eligible subjects ≤ 100 kg received 45 mg of ustekinumab subcutaneously, while subjects > 100 kg received 90 mg at weeks 0, 4, and 16. Clinical assessments of outcomes included: Physician Global Assessment (PGA), psolue and pain visual analogue scale (VAS) assessments. Preliminary results of 14 patients who have completed the primary efficacy endpoint of week 16 of the study indicate that ustekinumab is well tolerated and may be effective at improving PPP. Mean PGA improved from 5.3 to 1.9 (P ≤ 0.01) and DLQI improved from 12.6 to 6.1 (P ≤ 0.01) from week 0 to week 16. Ustekinumab is well tolerated and may be effective at improving clinical outcomes and quality of life in patients with moderate to severe palmar plantar psoriasis.

Commercial support: 100% is sponsored by Centocor.

Approved adalimumab dosing regimen associated with greater efficacy and lower cost per responder compared with 40 mg every other week dosing without initial 80 mg dose: Analysis of outcomes from adalimumab psoriasis clinical trial database

(Poster reference number 4952)
Alexa B. Kimball, Department of Dermatology, Harvard Medical School, Boston, MA, United States; Martin Oken, Abbott Immunology, Abbott Laboratories, Abbott Park, IL, United States; Parvez M. Mulani, Abbott Laboratories, Abbott Park, IL, United States; Yanzun Bao, Abbott Laboratories, Abbott Park, IL, United States.

Objective: Approved adalimumab dosing for moderate to severe psoriasis is 40 mg every other week (cow), after an initial 80 mg dose. This analysis compared outcomes with the approved dosing regimen vs no initiation dose (ID).

Methods: Patients were pooled from the CHAMPION (Comparative Study of HUMIRA vs Methotrexate or Placebo In PsOriasis PatieNts), REVEAL (Randomized Controlled Evaluation of Adalimumab Every Other Week Dosing in Moderate to Severe Psoriasis Trial), M02-528/529, and M03-658-659 and stratified into ID (90 mg at week 0; 40 mg cow from week 1) vs no initiation dose (NID) (40 mg cow from week 0) groups. Week 12 and 24 Psoriasis Area and Severity Index (PASI) response rates and Physician’s Global Assessment (PGA) scores were compared between groups using descriptive and regression analysis (controlling for baseline scores, REVEAL trial origin, age, sex, and race). Cost per PASI 75 responder was measured.

Results: Unadjusted ID group (N = 982) vs NID group (N = 258) had significantly (P ≤ 0.05) greater PASI 75 response rates (week 12: 71.8% vs 59.7%: week 24: 74.5% vs 64.0%) and greater PASI 90 response rates (week 12: 40.2% vs 32.4%; week 24: 52.2% vs 39.1%). Controlling for baseline covariates, compared with NID group, ID group was significantly (P ≤ 0.02) more likely to achieve PGA of ‘moderate’ or better (week 12 odds ratio [OR] = 3.32; week 24 OR = 5.67), PASI 75 response (week 12 OR = 1.73; week 24 OR = 1.70), and PASI 90 response (week 12 OR = 1.42; week 24 OR = 1.77). At week 24, ID group was projected to have $1275 lower costs per PASI 75 responder than NID group.

Conclusion: Adalimumab treatment with the approved dosing regimen is associated with significantly greater improvement in psoriasis severity symptoms compared with adalimumab treatment of 40 mg cow dosing without initial 80 mg dose.

Apremilast is effective in the treatment of nail psoriasis: Results from a phase IIb, randomized, controlled study

(Poster reference number 5559)
Kim Papp, MD, PhD, K. Papp Clinical Research Inc, Waterloo, Canada; Angela Hu, MS, Celgene Corporation, Warren, NJ, United States; Phoebe Rich, MD, Northwest Cutaneous Research Specialists, Portland, OR, United States; Robert Kelly, MD, Celgene Corporation, New Jersey, NJ, United States.

Background: Phosphodiesterase-4 (PDE4) is expressed in cells mediating immune response. Apremilast (APR) is a novel, orally available small molecule that specifically targets PDE4, thereby increasing cellular cAMP, which modulates multiple pro- and antiinflammatory mediators. We evaluated the clinical efficacy of APR in the treatment of nail psoriasis.

Methods: In a phase IIb, multicenter, double-blind, placebo (PBO)-controlled, dose-ranging study, subjects with moderate to severe plaque psoriasis (Psoriasis Area and Severity Index (PASI) ≥ 12; body surface area (BSA) ≥ 10%) were equally randomized to oral APR 10 mg (APR10), 20 mg (APR20), 30 mg (APR30) BID, or PBO for 16 weeks. The last 16 wk. Subjects were rerandomized to APR20 (PBO) or APR30 (PBO) at week 16. Subjects maintained their dosing through week 24. APR was significantly more subjects treated with APR20 (42.1%; P = 0.006) and APR30 (45.5%; P = 0.002) vs PBO (18.2%; APR10, 31.5%; NS). At week 24, median reductions in Nail Psoriasis Severity Index (NAPSI) of 15% and 10% (N = 221) had NAPSI-50 was achieved by 44.4% (APR10), 52.6% (APR20), 52.7% (APR30), 52.9% (P20), and 54.8% (P30) of subjects.

Conclusion: APR was previously shown to be effective in the treatment of plaque psoriasis. The current analysis demonstrates APR activity in difficult-to-treat nail psoriasis after 16 weeks of therapy, which appeared to continue through week 24. Phase III studies are under way and will further explore APR efficacy for treatment of nail psoriasis.

Apremilast is effective in the treatment of scalp and palmoplantar psoriatic lesions: Results from a phase IIb randomized, controlled study

(Poster reference number 5552)
Kim Papp, MD, PhD, K. Papp Clinical Research Inc, Waterloo, Canada; Angela Hu, MS, Celgene Corporation, Warren, NJ, United States; Norman Wasel, MD, Stratica Medical, Edmonton, Canada; Robert Day, PhD, Celgene Corporation, Warren, NJ, United States.

Background: Phosphodiesterase-4 (PDE4) is expressed in cells mediating immune response. Apremilast (APR) is a novel, orally available small molecule that specifically targets PDE4, thereby increasing cellular cAMP, which modulates multiple pro- and antiinflammatory mediators. We evaluated the clinical efficacy of APR in the treatment of scalp and palmoplantar (PP) psoriasis.

Methods: In a phase IIb, multicenter, double-blind, placebo (PBO)-controlled, dose-ranging study, subjects with moderate to severe plaque psoriasis (PASI ≥ 12; BSA ≥ 10%) were equally randomized to oral APR 10 mg (APR10), 20 mg (APR20), 30 mg (APR30) BID, or PBO. At week 16, PBO subjects were rerandomized to APR20 or APR30; the remaining subjects maintained their dosing through week 24. The efficacy of APR was evaluated using the Physician Global Assessment for lesions on the scalp (ScPGA; 0-5 scale) and palms/soles (PPPGA; 0-4 scale); exploratory efficacy endpoints were the proportion of subjects with baseline scores ≥ 5 achieving PGA scores of “clear” or “almost clear” (0-1) and “clear” “almost clear,” or “mild” (0-2) at weeks 16 and 24.

Results: Of the 352 subjects enrolled, 251 with moderate to very severe scalp psoriasis (PBO, n = 53; APR10, n = 62; APR20, n = 57; APR30, n = 59) qualified for the prespecified analysis. At week 16, more APR-treated subjects achieved ScPGA 0-1 (APR10 [22.6%], APR20 [45.6%], APR30 [44.1%]) vs PBO (15.1%). Improvements were still seen at week 24: 21.0% (APR10), 38.6% (APR20), and 40.7% (APR30). Of PBO subjects rerandomized to APR20 or APR30 at week 16, 43.4% achieved PGA 0-1 at week 24. At week 16, ScPGA 0-2 was achieved by 30.2% (PBO), 38.7% (APR10), 55.3% (APR20), and 59.3% (APR30) of subjects. At week 24, ScPGA 0-2 was achieved by 58.7% (APR10), 52.6% (APR20), and 52.5% (APR30) of subjects. A trend for efficacy was noted in 52 subjects with moderate or severe PPP psoriasis (PBO, n = 10; APR10, n = 9; APR20, n = 8; APR30, n = 9). At weeks 16 and 24, 66.7% and 77.8% of APR30-treated subjects achieved PPSG 0-1 (PBO, 20.0% and 30.0%) and 88.9% and 77.8% achieved PPSGA 0-2 (PBO, 50.0% for both).

Conclusion: APR was previously shown to be effective in the treatment of plaque psoriasis. The current analysis demonstrated APR activity in difficult-to-treat scalp psoriasis lesions. The results also suggest activity in treating PPP psoriasis lesions. Phase III studies are under way and will further explore APR efficacy for treatment of scalp and PPP psoriasis.

Approved adalimumab dosing regimen associated with greater efficacy and lower cost per responder compared with 40 mg every other week dosing without initial 80 mg dose: Analysis of outcomes from adalimumab psoriasis clinical trial database

(April 2012) J Am Acad Dermatol AB185